



Synlogic Announces Second Quarter 2019 Conference Call and Webcast

August 1, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2019-- [Synlogic, Inc. \(Nasdaq: SYBX\)](#), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market closes on Thursday, August 8, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 6968273. Participants may access the live webcast via a link on the Synlogic website in the [Events Calendar](#) of the Investors and Media section. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company's website.

About Synlogic

Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease. Synthetic Biotic medicines are designed to act locally and have a systemic effect to address disease in patients. Synlogic's two lead programs, SYN1020 and SYN1618, are orally administered and target hyperammonemia as a result of liver damage or genetic disease, and phenylketonuria, respectively. Synlogic is also developing SYN1891 as an intratumorally-administered Synthetic Biotic medicine for the treatment of cancer. In addition, the company is leveraging the broad potential of its platform to create additional Synthetic Biotic medicines for the treatment of liver disease, as well as inflammatory and immune disorders including Synlogic's collaboration with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190801005651/en/>

Source: Synlogic, Inc.

MEDIA CONTACT:

Caroline Rufo, Ph.D.
MacDougall
Phone: 781-235-3060
Email: crufom@macbiocom.com

INVESTOR CONTACT:

Elizabeth Wolffe, Ph.D.
Synlogic, Inc.
Phone: 617-207-5509
Email: liz@synlogictx.com